Comments
Zydus Cadila’s wholly-owned subsidiary Alidac Pharmaceuticals has not received any observation from the US health regulator after the closure of inspection of its manufacturing facility located at SEZ, Ahmedabad.
“The US Food and Drug Administration (USFDA) inspected the manufacturing facility of our wholly-owned subsidiary, Alidac Pharmaceuticals Ltd, located at SEZ, Ahmedabad from May 28 to June 5, 2018. At the end of the inspection, no observation (483) is issued,” the company said in a BSE filing today.
The site manufactures oncology injectables for the regulated markets, it added.
Shares of Cadila Healthcare, the listed entity of the group, were trading up by 2.01 per cent at Rs 355.65 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.